AXT's Split Personality: Institutional Accumulation Collides With a 188% Volatility Storm

AXT shares fell 12% Friday to €50.76 amid profit-taking, but indium phosphide supply shortage and BlackRock stake support long-term bull case.

There are moments when a stock's price action and its underlying business narrative diverge so sharply that they might as well be describing two different companies. AXT is living that contradiction right now. The California-based compound semiconductor substrate maker has spent the past week watching its shares shed value at a dizzying clip — down 12 percent on Friday alone to €50.76 — even as the fundamental story around its core product, indium phosphide, has arguably never been more compelling.

The sell-off, attributed to profit-taking rippling across the entire indium phosphide supply chain, comes on the heels of a staggering run. Shares remain up 298 percent since the start of the year, though the last seven trading sessions have carved out a 16 percent decline. The stock now sits 61 percent below its 52-week high, reached just over two months ago, and trades 9.6 percent beneath its 50-day moving average of €56.13. For a name carrying an annualized volatility rate of 188 percent, the swings are jarring — but they're also, by this point, familiar.

The Supply Squeeze That Won't Quit

What makes the current pullback feel more like technical digestion than fundamental deterioration is the backdrop against which it's happening. A report out of Taipei flagged what's being described as the most severe indium phosphide shortage the semiconductor industry has ever witnessed, with wafer prices expected to climb more than 10 percent in the fourth quarter. For AXT, which manufactures the substrates that underpin optical connectivity in AI data centers, tight supply should translate into pricing power.

That thesis got a jolt of validation on August 17, when shares jumped 18 percent on the back of the Taipei report. But the same supply dynamics that boost prices also introduce planning headaches. Wedbush, according to market reports, has pointed to potential delays out of China as a headwind — a reminder that AXT's value chain runs through geopolitically sensitive territory where indium phosphide has become the pinch point.

The ambivalence explains why institutional money and short-term traders are behaving so differently. BlackRock added 4,653,059 shares during the second quarter, lifting its stake to 7.1 percent of the company — though a separate filing suggests the position may now stand at 7.75 percent. GSA Capital Partners also established a new position. These aren't the moves of investors trading the daily chart; they're bets on structural demand outstripping supply for years to come.

Insiders and ETFs Tell a Different Story

Not everyone is leaning in. Director Leonard J. LeBlanc sold 4,000 shares on August 17 for roughly $384,000, retaining about 113,000 shares afterward. A single director taking some chips off the table hardly constitutes a bearish signal on its own, but it does cut against the narrative of universal conviction at current levels.

There's also the matter of the leveraged Tradr ETFs on AXTI that launched on August 18. Investors had been positioning ahead of the debut, and these products — which must be rebalanced daily — tend to amplify moves in both directions. For a stock already among the most volatile in the market, the addition is akin to pouring accelerant on a fire that was never struggling for fuel.

A Split Analyst Picture

The ratings landscape offers little clarity. Zacks Research upgraded the stock to "Strong Buy" in early August, while Weiss Ratings simultaneously maintained a sell recommendation, albeit nudging it up from "Sell (D-)" to "Sell (D+)" on August 14. The broader consensus, based on six firms as of August 22, sits at "Moderate Buy."

These automated scoring models often say more about their methodologies than the underlying business. Still, the divergence underscores just how wide the range of opinion has become.

What's Next

The company has a busy conference calendar that could provide fresh data points: Needham on August 20, B. Riley Securities in New York on September 10, and the Morgan Stanley ASIA Best Corporate Day on September 21-22, also in New York. These appearances offer AXT a platform to reinforce the demand narrative around indium phosphide — or, alternatively, to expose cracks in it.

The long-term contract with Lumentum, which runs through 2031 and includes prepayments of $87 million to be offset against future deliveries, remains the anchor of the bull case. Combined with the reported supply shortage and BlackRock's accumulation, the fundamental core appears intact.

But the 188 percent volatility figure is not an abstraction. It's a warning that anyone holding this stock should expect the ride to remain violent. The question isn't whether AXT's underlying business is sound — it's whether investors can stomach the gap between where the story is heading and where the tape is taking them in the meantime.